Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design

Author： Meine Rosanna   Becker Walter   Falke Hannes   Preu Lutz   Loaëc Nadège   Meijer Laurent   Kunick Conrad  

Publisher： MDPI

E-ISSN： 1420-3049|23|2|64-64

ISSN： 1420-3049

Source： Molecules, Vol.23, Iss.2, 2018-01, pp. : 64-64

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Native Mass Spectrometry in Fragment-Based Drug Discovery

By Pedro Liliana   Quinn Ronald J.  

Molecules, Vol. 21, Iss. 8, 2016-07 ,pp. : 984-984

MDPI

Access to resources Recommend Favorite

Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part II

By Foucourt Alicia   Hédou Damien   Dubouilh-Benard Carole   Girard Angélique   Taverne Thierry   Casagrande Anne-Sophie   Désiré Laurent   Leblond Bertrand   Besson Thierry  

Molecules, Vol. 19, Iss. 10, 2014-09 ,pp. : 15411-15439

MDPI

Access to resources Recommend Favorite

Design and Synthesis of Thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part I

By Foucourt Alicia   Hédou Damien   Dubouilh-Benard Carole   Désiré Laurent   Casagrande Anne-Sophie   Leblond Bertrand   Loäec Nadège   Meijer Laurent   Besson Thierry  

Molecules, Vol. 19, Iss. 10, 2014-09 ,pp. : 15546-15571

MDPI

Access to resources Recommend Favorite

Applications of 19F-NMR in Fragment-Based Drug Discovery

By Norton Raymond S.   Leung Eleanor W. W.   Chandrashekaran Indu R.   MacRaild Christopher A.  

Molecules, Vol. 21, Iss. 7, 2016-07 ,pp. : 860-860

MDPI

Access to resources Recommend Favorite

Prediction of Positions of Active Compounds Makes It Possible To Increase Activity in Fragment-Based Drug Development

By Fukunishi Yoshifumi  

Pharmaceuticals, Vol. 4, Iss. 5, 2011-05 ,pp. : 758-769

MDPI

Access to resources Recommend Favorite